ARCH Venture Fund XIII, L.P.

ARCH Venture Fund XIII, L.P., 10% Owner, accounts for 2 disclosed filings worth $12.5M, all concentrated in Lyell Immunopharma, Inc. (LYEL), active 2025–2026. The record is heavily weighted toward buying, with $12.5M in purchases against $0 in sales. The largest single open-market purchase on record is $12.5M in Lyell Immunopharma, Inc.. Data is sourced from official SEC Form 3, 4, and 5 filings.